A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines

References

• WHO. How to develop and implement a national drug policy. Geneva: World Health Organisation. 2001.
   Google Scholar
• WHO. The selection of essential medicines. WHO policy perspectives on medicines, June. Geneva: World Health Organisation. 2002. Available from: http://whqlibdoc.who.int/hq/2002/WHO_EDM_2002.2.pdf [cited: June 18 2010]..
   Google Scholar
• Quick JD. Managing drug supply: the selection, procurement, distribution, and use of pharmaceuticals. Kumarian Press books on international development. 2nd ed. West HartfordCT: Kumarian Press. 1997.
   Google Scholar
• Laing R, Waning B, Gray A, Ford N, 't Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003; 9370: 1723–9.
   Google Scholar
• Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001; 1: 13–20.
   Google Scholar
• Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004; 7475: 1169–72.
   Google Scholar
• WHO. Country cooperation strategy for WHO and the Libyan Arab Jamahiriya 2005–2009. Cairo: Regional Office for the Eastern Mediterranean. Available from: http://www.who.int/countryfocus/cooperation_strategy/ccs_lby_en.pdf [cited: June 18 2010]..
   Google Scholar
• Faitoori A, Mgairbi Z, Alfakri M, Younis J, Hodana B, Bashir A, et al.. A study of the Libyan Medicines Situation. Libyan Central Bank. Libya, 2003
   Google Scholar
• Ekhshaibah E. Channels of medical supply in Libya. In: The Fifth National Pharmaceutical Sciences Conference, Benghazi, Libya, 22–24 April 2005, p. 1–69.
   Google Scholar
• GPC. The General People's Committee, Tripoli. ; 2009. Available from: http://www.gpc.gov.ly/html/home.php [cited 19 April 2010].
   Google Scholar
• Jafarov A. Selection of essential drug lists in Central Asian Republics. Comparison and discrepancies. ; 2002. Available from: http://dcc2.bumc.bu.edu/richardl/RPM + _Project/Aziz.htm [cited 21 June 2010].
   Google Scholar
• Cohen J, Improving transparency in pharmaceutical systems: strengthening critical decision points against corruption. Latin American and Caribbean Region, Human Development Network. 2002. Available from: http://www.u4.no/pdf/?file = /themes/health/cohen_wb_paper_pharma2002.pdf [cited: June 18 2010]..
   Google Scholar
• WHO. World Health Organization, Countries, Libya. ; 2010. Available from: http://www.who.int/countries/lby/en/ [cited 21 June 2010].
   Google Scholar
• WHO. The selection and use of essential medicines. Report of the WHO Expert Committee (including the 15th Model list of essential medicines). 2007. Geneva: World Health Organisation.
   Google Scholar
• Maher D, Uplekar M, Blanc L, Raviglione M. Treatment of tuberculosis. BMJ. 2003; 7419: 822–3.
   Google Scholar
• WHO. Fixed dose combinations for HIV/AIDS, tuberculosis, and malaria. Current status and future challenges from clinical, regulatory, intellectual property, and production perspectives. Geneva: World Health Organisation. 2003.
   Google Scholar
• Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs. 2003; 6: 535–53.
   Google Scholar
• Blomberg B, Spinaci S. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bulletin of the World Health Organization. 2001; 1: 61–8.
   Google Scholar
• Bartacek A, Schütt D, Panosch B, Borek M, Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009: 760–6.
   Web of Science ®Google Scholar
• El Taguri A, Elkhammas E, Bakoush O, Ashammakhi N, Baccoush M, Betilmal I. Libyan National Health Services: the need to move to management-by-objectives. LJM. 2008; 2: 113–21.
   Google Scholar
• Nunn P, Porter J, Winstanley P. Thiacetazone – avoid like poison or use with care?. Trans R Soc Trop Med Hyg. 1993; 5: 578–82.
   Google Scholar
• Rieder HL, Arnadottir T, Trébucq D, Enarson DA. Tuberculosis treatment: dangerous regimens?. Int J Tuberc Lung Dis. 2001; 1: 1–3.
   Google Scholar
• Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, et al.. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006; 8: 1163–9.
   Google Scholar
• Khatri M, Shafi M, Banghazil M. Cutaneous leishmaniasis with unusual presentation. Indian J Dermatol Venereol Leprol. 1999; 3: 140–2.
   Google Scholar
• Charles BGP, Townsend SRB, Steer PAF, Flenady VJRM, Gray PHF, Shearman AM. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit. 2008; 6: 709–16.
   Google Scholar
• Ghenghesh KS, Franka EA, Tawil KA, Abeid S, Ali MB, Taher IA, et al.. Infectious acute diarrhea in Libyan children: causative agents, clinical features, treatment and prevention. Libyan J Infect Dis. 2008; 1: 10–19.
   Google Scholar
• WHO. Global use of rotavirus vaccines recommended, media release. Geneva: World Health Organisation. 2009. Available from: http://www.who.int/mediacentre/news/releases/2009/rotavirus_vaccines_20090605/en/index.html [cited 19 April 2009].
   Google Scholar
• Peter ALJ, Viraraghavan T. Thallium: a review of public health and environmental concerns. Environ Int. 2005; 4: 493–501.
   Google Scholar
• Geller RJ, Barthold C, Saiers JA, Hall AH. Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. Pediatrics. 2006; 5: 2146–58.
   Google Scholar
• Miller M, Patel M, Coon T. Prussian blue for treatment of thallium overdose in the US. Hospital Pharmacy. 2005; 40: 796–7.
   Google Scholar
• Borron SW. Recognition and treatment of acute cyanide poisoning. J Emerg Nurs. 2006; 4: S12–S18.
   Google Scholar
• Meinking TL, Vicaria M, Eyerdam DH, Villar ME, Reyna S, Suarez G. Efficacy of a reduced application time of ovide lotion (0.5% malathion) compared to nix creme rinse (1% permethrin) for the treatment of head lice. Pediatric Dermatology. 2004; 6: 670–4.
   Google Scholar
• Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician. 2002; 3: 455–64.
   Google Scholar
• Smilack JD. The tetracyclines. Mayo Clin Proc. 1999; 7: 727–9.
   Google Scholar
• Jabbari B, Bryan GE, Marsh EE, Gunderson CH. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol. 1985; 5: 480–1.
   Google Scholar